NCT04872348

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in pseudophakic eyes with mild to moderate primary open angle glaucoma (POAG) at least 150 days prior to enrollment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2021

Typical duration for all trials

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 29, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 4, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

July 1, 2021

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 2, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 2, 2023

Completed
1.5 years until next milestone

Results Posted

Study results publicly available

May 11, 2025

Completed
Last Updated

May 22, 2025

Status Verified

May 1, 2025

Enrollment Period

2.3 years

First QC Date

April 29, 2021

Results QC Date

March 10, 2025

Last Update Submit

May 12, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in Intraocular Pressure (IOP)

    Percent change in unmedicated diurnal intraocular pressure (DIOP/washout) or medicated intraocular pressure (IOP/no washout) compared to baseline.

    18 months

  • Change in Number of Medications

    Mean change in the number of ocular hypotensive medications compared to baseline.

    18 months

Study Arms (2)

Eyes receiving OMNI intervention after medication washout

Device: OMNI® Surgical System

Eyes receiving OMNI intervention without medication washout

Device: OMNI® Surgical System

Interventions

The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

Eyes receiving OMNI intervention after medication washoutEyes receiving OMNI intervention without medication washout

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Subjects treated with OMNI® Surgical System as a standalone procedure in pseudophakic eye with mild to moderate primary open angle glaucoma

You may qualify if:

  • Treated with OMNI® Surgical System as a standalone procedure in pseudophakic eye with mild to moderate primary open angle glaucoma at least 150 days prior to enrollment.

You may not qualify if:

  • Systemic disease that, in the opinion of the Investigator, would put the subject's health at risk and/or prevent completion of required study visits.
  • Ocular pathology which, in the Investigator's judgment, would either place the subject at increased risk of complications or contraindicate washout, place the subject at risk of significant vision loss during the study period or interfere with compliance to elements of the study protocol (e.g., returning to Investigator's office for follow-up visits).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Eye Specialists of Georgia

Atlanta, Georgia, 30315, United States

Location

Grene Vision Group

Wichita, Kansas, 62708, United States

Location

Minnesota Eye Consultants

Bloomington, Minnesota, 55431, United States

Location

Northern New Jersey Eye Institute

Orange, New Jersey, 07079, United States

Location

Oklahoma Eye Surgeons

Oklahoma City, Oklahoma, 73112, United States

Location

University Eye Specialists

Maryville, Tennessee, 37803, United States

Location

El Paso Eye Surgeons

El Paso, Texas, 79902, United States

Location

Ophthalmology Associates - Fort Worth

Fort Worth, Texas, 76102, United States

Location

Utah Eye Centers

Ogden, Utah, 84403, United States

Location

Virginia Eye Consultants

Norfolk, Virginia, 23502, United States

Location

MeSH Terms

Conditions

Glaucoma, Open-Angle

Condition Hierarchy (Ancestors)

GlaucomaOcular HypertensionEye Diseases

Results Point of Contact

Title
VP, Medical and Clinical Affairs
Organization
Sight Sciences, Inc.

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 29, 2021

First Posted

May 4, 2021

Study Start

July 1, 2021

Primary Completion

November 2, 2023

Study Completion

November 2, 2023

Last Updated

May 22, 2025

Results First Posted

May 11, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations